A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Inclusion Criteria: * Male or female subject aged 18-70 years (both inclusive) * Type 2 diabetes mellitus (as diagnosed clinically) for ≥ 12 months * HbA1c level between 7.5% and 9.5% (both inclusive) * Body mass index between 20.0 and 40.0 kg/m2 (both inclusive) * Treated with once daily injections with insulin glargine U-100 for ≥ 3 months prior to screening Exclusion Criteria: * Type 1 diabetes mellitus * Known or suspected allergy to the IMPs or related products * Previous participation in this trial. Participation is defined as randomised. * Receipt of any medicinal product in clinical development within 60 days prior to this trial. * Clinically significant abnormal haematology, biochemistry, urinalysis or coagulation screening tests, as judged by the Investigator considering the underlying disease * Supine blood pressure at screening outside the range of 90-160 mmHg for systolic or 50-95 mmHg for diastolic and/or resting supine heart rate outside the range 50-90 beats per minute. This exclusion criterion also pertains to subjects being on antihypertensives. * Current treatment with premixed or intermediate insulin products, or with long acting insulins other than insulin glargine U-100. The use of short or rapid acting prandial insulin products will be allowed provided their use has been stable for ≥ 3 months prior to screening. * Use of GLP-1 receptor agonists or oral antidiabetic drugs (OADs) other than stable intake of metformin alone or metformin in combination with a DPP-4 inhibitor within 4 weeks prior to screening * Women of child bearing potential not willing to use contraceptive methods.